Last reviewed · How we verify
Dexamethasone physician choice
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm. Used for Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus), Cerebral edema and increased intracranial pressure, Severe COVID-19 (respiratory support requirement).
At a glance
| Generic name | Dexamethasone physician choice |
|---|---|
| Also known as | dexamethasone sodium phosphate, dexamethasone acetate |
| Sponsor | Ottawa Hospital Research Institute |
| Drug class | Glucocorticoid (corticosteroid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Oncology (supportive care) |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone enters cells and binds to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory responses. It is approximately 25–30 times more potent than the natural glucocorticoid cortisol.
Approved indications
- Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus)
- Cerebral edema and increased intracranial pressure
- Severe COVID-19 (respiratory support requirement)
- Chemotherapy-induced nausea and vomiting (CINV)
- Adrenocortical insufficiency
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia and mood disturbances
- Increased infection risk
- Osteoporosis (with chronic use)
- Gastrointestinal upset
- Immunosuppression
Key clinical trials
- Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors (PHASE2)
- Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis (PHASE3)
- Non-steroidal Anti-inflammatory Drugs in Pleurodesis (PHASE2)
- Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients (PHASE4)
- Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone physician choice CI brief — competitive landscape report
- Dexamethasone physician choice updates RSS · CI watch RSS
- Ottawa Hospital Research Institute portfolio CI